Creoptix AG closes CHF8m financing round
The financing round was led by Swisscanto Invest by Zürcher Kantonalbank and joined by Waters Corporation as well as existing private investors....
Successful EFIB in Brussels
More than 260 companies with 480 delegates from 30 countries joined for this year’s “European Forum for industrial Biotechnology and Bioeconomy”...
EMA greenlights new medicines
With the three innovative medicines and four generics the number of recommended medicines raised to 47 in 2019. The Committee saw a positive...
BioNTech pulls in massive €290m financing
Two thirds of the funding came from new investors, said the Mainz-based mRNA immunotherapy specialist. However, existing investors were also on...
Better TNF∝ receptor blockers on the horizon
Penny Morton and colleages from Kings College in London uncovered how the organisation of the receptor for tumor necrosis factor ∝(TNFR1) within the...
MS: Polpharma joins forces with Sandoz
Natalizumab, which is currently being marketed by Biogen, is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is a...